Sulforaphane Adjunct to Methylphenidate for Attention-deficit/Hyperactivity Disorder: A Randomized, Double-blind, Placebo-controlled Trial
Ghannadi F, Shamabadi A, Talebinejad MS, Naseh E, Heidari E, Paknezhad S, Mohammadi M, Akhondzadeh S
Clinical neuropharmacology · 0 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
- Consumo medido con
- No se indica
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2025-10-30 · Clin Neuropharmacol · vol. 48 · número 6 · págs. 181–187
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 0 citas · más que el 55% de estudios similares · 0.0× el promedio de su campo
- Referencias
- 27 trabajos
- Acceso
- De pago
- Áreas de investigación
- Attention Deficit Hyperactivity Disorder · Saffron Plant Research Studies · Schizophrenia research and treatment
- Palabras clave
- sulforaphane, methylphenidate, attention deficit hyperactivity disorder, children, adjunctive therapy, inattention, hyperactivity/impulsivity, neuroprotection, anti-inflammatory activity, antioxidant activity, treatment response
- MeSH
- humans, methylphenidate, isothiocyanates, sulfoxides, central nervous system stimulants, treatment outcome, drug therapy, combination, double-blind method, attention deficit disorder with hyperactivity, child, female, male
8 autores
- Farnaz Ghannadi🇮🇷 · autor de correspondenciaRoozbeh Hospital; Tehran University of Medical Sciences
- Ahmad Shamabadi🇮🇷 · autor de correspondenciaRoozbeh Hospital; Tehran University of Medical Sciences
- Mohammadsaleh Talebinejad🇮🇷 · autor de correspondenciaRoozbeh Hospital; Tehran University of Medical Sciences
- Ehsan Naseh🇮🇷 · autor de correspondenciaRoozbeh Hospital; Tehran University of Medical Sciences
- Ehsan Heidari
- Sepideh Paknezhad🇮🇷 · autor de correspondenciaRoozbeh Hospital; Tehran University of Medical Sciences
- MohammadReza Mohammadi🇮🇷 · autor de correspondenciaRoozbeh Hospital; Tehran University of Medical Sciences
- Shahin Akhondzadeh🇮🇷 · autor de correspondenciaRoozbeh Hospital; Tehran University of Medical Sciences
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objectives
Available treatment strategies for attention-deficit/hyperactivity disorder (ADHD) encounter significant limitations and, thus, necessitate novel therapeutic approaches. In this regard, this study investigated the effects of sulforaphane due to its neuroprotective, anti-inflammatory, and antioxidant properties.
Methods
Seventy ADHD outpatients aged 6 to 11 were equally assigned to receive methylphenidate (0.3 to 1.5 mg/kg/d) plus either sulforaphane 30 mg/d or matched placebo for 8 weeks. The teacher and parent ADHD rating scale (ADHD-RS) was used to assess their symptoms at baseline and weeks 4 and 8. The patients were also evaluated for side effects.
Results
Thirty-two patients in the sulforaphane group and 31 in the placebo group completed the study with comparable baseline demographic and clinical characteristics (Ps>0.05). There were significant time-treatment interaction effects on the ADHD-RS total, inattention, and hyperactivity-impulsivity scores rated by teachers (=0.245, 0.203, and 0.246, respectively) and parents (=0.265, 0.283, and 0.159, respectively). Affirmatively, their reductions were significantly greater in the sulforaphane group until the endpoint rated by teachers (Cohen ds=1.192, 1.055, and 1.220, respectively) and parents (Cohen's ds=1.344, 1.446, and 0.966, respectively). Better response to treatment (≥40% reduction in ADHD-RS total scores), robust improvement (≥50% reduction in ADHD-RS total scores), and remission (an ADHD-RS total score of ≤18) rates were obtained in the sulforaphane group until the endpoint (Ps0.05).
Conclusions
Sulforaphane adjunct to methylphenidate was beneficial for inattention, hyperactivity-impulsivity, and total symptoms of children with ADHD safely and tolerably.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.